Last 7 days
-2.5%
Last 30 days
-4.1%
Last 90 days
-5.3%
Trailing 12 Months
11.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 439.0B | 324.2B | -3.12% | -7.42% | 21.82 | 1.35 | 12.71% | 16.40% |
CI | 91.1B | 180.5B | -13.92% | 6.07% | 13.64 | 1.92 | 3.70% | 24.58% |
HUM | 61.8B | 92.9B | -4.10% | 11.05% | 22.03 | 0.67 | 11.81% | -4.33% |
CNC | 35.3B | 144.5B | -9.19% | -25.06% | 29.38 | 0.24 | 14.74% | -10.76% |
MID-CAP | ||||||||
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
HQY | 4.9B | 831.2M | -10.57% | -12.87% | -83.44 | 5.9 | 12.11% | -862.52% |
AMN | 3.4B | 5.2B | -8.25% | -21.56% | 7.71 | 0.65 | 31.60% | 35.63% |
CRVL | 3.2B | 704.5M | 4.54% | 11.22% | 47.88 | 4.61 | 13.56% | 10.15% |
PDCO | 2.6B | 6.4B | -2.27% | -16.61% | 13.15 | 0.4 | -0.52% | 17.01% |
SMALL-CAP | ||||||||
ADUS | 1.7B | 951.1M | -1.69% | 17.81% | 36.04 | 1.74 | 10.02% | 1.99% |
TVTY | 1.6B | - | 0.59% | 17.88% | 18.77 | 3.24 | - | - |
RDNT | 1.3B | 1.4B | 14.63% | 3.78% | 123.09 | 0.92 | 8.74% | -56.93% |
BKD | 561.7M | 2.8B | -12.95% | -59.69% | -2.36 | 0.2 | 2.43% | -140.13% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 1.5% | 92,870 | 91,485 | 89,383 | 86,366 | 83,064 |
S&GA Expenses | 1.2% | 12,671 | 12,515 | 12,057 | 11,000 | 10,121 |
EBITDA | 0.6% | 4,718 | 4,690 | 4,989 | 4,590 | - |
EBITDA Margin | -0.9% | 0.05* | 0.05* | 0.06* | 0.05* | - |
Earnings Before Taxes | -0.3% | 3,568 | 3,579 | 3,918 | 3,534 | 3,354 |
EBT Margin | -1.8% | 0.04* | 0.04* | 0.05* | 0.04* | - |
Interest Expenses | 4.4% | 401 | 384 | 370 | 348 | 326 |
Net Income | 0.0% | 2,806 | 2,807 | 3,143 | 3,035 | 2,933 |
Net Income Margin | -1.5% | 0.03* | 0.03* | 0.04* | 0.04* | - |
Free Cahsflow | -58.7% | 3,467 | 8,385 | 2,729 | 2,080 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -15.2% | 43,055 | 50,765 | 46,820 | 46,308 | 44,358 |
Current Assets | -22.3% | 26,183 | 33,711 | 27,217 | 26,840 | 24,893 |
Cash Equivalents | -62.7% | 5,061 | 13,558 | 5,153 | 4,864 | 3,394 |
Net PPE | 0.1% | 3,221 | 3,218 | 3,121 | 3,189 | 3,073 |
Goodwill | 0.5% | 9,142 | 9,096 | 8,911 | 11,139 | 11,092 |
Liabilities | -19.6% | 27,685 | 34,448 | 31,310 | 30,966 | 28,255 |
Current Liabilities | -31.4% | 17,178 | 25,051 | 17,839 | 17,532 | 15,331 |
LT Debt, Non Current | 15.9% | 9,034 | 7,798 | 11,290 | 11,285 | 10,541 |
Shareholder's Equity | -6.2% | 15,311 | 16,317 | 15,510 | 15,342 | 16,080 |
Retained Earnings | -0.4% | 25,492 | 25,606 | 24,511 | 23,915 | 23,086 |
Additional Paid-In Capital | 0.4% | 3,246 | 3,234 | 3,153 | 3,103 | 3,082 |
Accumulated Depreciation | - | 2,874 | - | - | - | - |
Shares Outstanding | 0.0% | 127 | 127 | 126 | - | - |
Minority Interest | -6.3% | 59.00 | 63.00 | 20.00 | 23.00 | 23.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -52.3% | 4,587 | 9,618 | 4,000 | 3,401 | 2,262 |
Share Based Compensation | -2.3% | 216 | 221 | 189 | 184 | 180 |
Cashflow From Investing | -947.9% | -1,006 | -96.00 | -6,023 | -5,716 | -6,556 |
Cashflow From Financing | -614.2% | -1,914 | -268 | 3,865 | 3,302 | 3,015 |
Dividend Payments | 2.6% | 392 | 382 | 372 | 362 | 354 |
Buy Backs | 95.0% | 2,096 | 1,075 | 1,074 | 1,073 | 79.00 |
58.5%
19.2%
0%
Y-axis is the maximum loss one would have experienced if Humana was unfortunately bought at previous high price.
22.4%
15.5%
13.2%
18.5%
FIve years rolling returns for Humana.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-28 | Acrisure Capital Management, LLC | new | - | 585,433 | 585,433 | 0.65% |
2023-03-24 | Longbow Finance SA | new | - | 15,333,900 | 15,333,900 | 2.06% |
2023-03-23 | MetLife Investment Management, LLC | reduced | -1.83 | 658,244 | 18,754,900 | 0.15% |
2023-03-17 | American Portfolios Advisors | reduced | -7.59 | -18,687 | 425,047 | 0.02% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 8.63 | 99,705 | 774,705 | 0.02% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -7.18 | -1,818,050 | 88,317,900 | 0.10% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 1,170 | 28,170 | -% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 3.15 | 23,316 | 223,316 | 0.02% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | reduced | -0.24 | 53,794 | 1,062,790 | 0.07% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 4.14 | 274,000 | 3,028,000 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | price t rowe associates inc /md/ | 6.0% | 7,623,150 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.97% | 11,357,974 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 6.01% | 7,611,181 | SC 13G | |
Jan 25, 2023 | blackrock inc. | 9.2% | 11,628,073 | SC 13G/A | |
Jun 09, 2022 | blackrock inc. | 10.1% | 12,733,508 | SC 13G/A | |
Feb 14, 2022 | price t rowe associates inc /md/ | 8.1% | 10,508,002 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 7.79% | 10,008,322 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 8.8% | 11,254,355 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 287.83 -41.06% | 417.26 -14.56% | 616.10 26.16% | 806.15 65.07% | 935.13 91.48% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 27, 2023 | 3 | Insider Trading | |
Mar 23, 2023 | 4 | Insider Trading | |
Mar 13, 2023 | 8-K | Current Report | |
Mar 08, 2023 | ARS | ARS | |
Mar 08, 2023 | DEF 14A | DEF 14A | |
Mar 08, 2023 | DEFA14A | DEFA14A | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 424B5 | Prospectus Filed | |
Mar 01, 2023 | 8-K | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-01 | Feinberg David T | acquired | - | - | 441 | - |
2023-02-28 | JONES DAVID A JR/KY | gifted | - | - | -10,000 | - |
2023-02-27 | Ventura Joseph C | gifted | - | - | -69.00 | chief legal officer |
2023-02-27 | BROUSSARD BRUCE D | sold | -8,890,230 | 505 | -17,575 | president & ceo |
2023-02-27 | Huval Timothy S. | sold | -1,341,080 | 510 | -2,628 | chief administrative officer |
2023-02-27 | Ventura Joseph C | sold | -1,040,330 | 507 | -2,048 | chief legal officer |
2023-02-24 | BROUSSARD BRUCE D | acquired | - | - | 28,494 | president & ceo |
2023-02-24 | Huval Timothy S. | acquired | - | - | 4,306 | chief administrative officer |
2023-02-24 | BROUSSARD BRUCE D | sold (taxes) | -5,571,340 | 510 | -10,919 | president & ceo |
2023-02-24 | Fleming William Kevin | sold (taxes) | -919,457 | 510 | -1,802 | seg pres, pharmacy sol & ccao |
CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Services | Health Care [Member] | Health Care [Member] | Health Care [Member] |
Revenues: | |||
Premiums | $ 87,712 | $ 79,822 | $ 74,186 |
Services | 4,776 | 3,055 | 1,815 |
Investment income | 382 | 187 | 1,154 |
Total revenues | 92,870 | 83,064 | 77,155 |
Operating expenses: | |||
Benefits | 75,690 | 69,199 | 61,628 |
Operating costs | 12,671 | 10,121 | 10,052 |
Depreciation and amortization | 709 | 596 | 489 |
Total operating expenses | 89,070 | 79,916 | 72,169 |
Income from operations | 3,800 | 3,148 | 4,986 |
Gain on sale of KAH Hospice | (237) | 0 | 0 |
Interest expense | 401 | 326 | 283 |
Other expense (income), net | 68 | (532) | 103 |
Income before income taxes and equity in net (losses) earnings | 3,568 | 3,354 | 4,600 |
Provision for income taxes | 762 | 485 | 1,307 |
Equity in net (losses) earnings | (4) | 65 | 74 |
Net income | 2,802 | 2,934 | 3,367 |
Net loss (income) attributable to noncontrolling interests | 4 | (1) | 0 |
Net income attributable to Humana | $ 2,806 | $ 2,933 | $ 3,367 |
Basic earnings per common share (in dollars per share) | $ 22.20 | $ 22.79 | $ 25.47 |
Diluted earnings per common share (in dollars per share) | $ 22.08 | $ 22.67 | $ 25.31 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 5,061 | $ 3,394 |
Investment securities | 13,881 | 13,192 |
Receivables, net of allowances of $70 in 2022 and $83 in 2021 | 1,674 | 1,814 |
Other current assets | 5,567 | 6,493 |
Total current assets | 26,183 | 24,893 |
Property and equipment, net | 3,221 | 3,073 |
Long-term investment securities | 380 | 780 |
Goodwill | 9,142 | 11,092 |
Equity method investments | 749 | 141 |
Other long-term assets | 3,380 | 4,379 |
Total assets | 43,055 | 44,358 |
Current liabilities: | ||
Benefits payable | 9,264 | 8,289 |
Trade accounts payable and accrued expenses | 5,238 | 4,509 |
Book overdraft | 298 | 326 |
Unearned revenues | 286 | 254 |
Short-term debt | 2,092 | 1,953 |
Total current liabilities | 17,178 | 15,331 |
Long-term debt | 9,034 | 10,541 |
Other long-term liabilities | 1,473 | 2,383 |
Total liabilities | 27,685 | 28,255 |
Commitments and contingencies (Note 17) | ||
Stockholders' Equity: | ||
Preferred stock, $1 par; 10,000,000 shares authorized; none issued | 0 | 0 |
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,666,598 shares issued at December 31, 2022 and 198,648,742 shares issued at December 31, 2021 | 33 | 33 |
Capital in excess of par value | 3,246 | 3,082 |
Retained earnings | 25,492 | 23,086 |
Accumulated other comprehensive (loss) income | (1,304) | 42 |
Treasury stock, at cost, 73,691,955 shares at December 31, 2022 and 69,846,758 shares at December 31, 2021 | (12,156) | (10,163) |
Total stockholders' equity | 15,311 | 16,080 |
Noncontrolling interests | 59 | 23 |
Total equity | 15,370 | 16,103 |
Total liabilities and equity | $ 43,055 | $ 44,358 |